This consortium of industry, academia, patient representatives, regulatory and other government agencies, the National MS Society, and the Critical Path Institute agreed to next steps for collecting, standardizing and analyzing data from clinical trials of MS therapies and other related research to develop a new ???clinician-reported outcome measure.???